^
Association details:
| Biomarker: | RAS wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A study with two treatment arms to assess the efficacy of FOLFIRI (chemotherapy regimen with folinic acid, fluorouracil and irinotecan) in combinations with one specific antibody (cetuximab vs. bevacizumab) in the first-line treatment of metastatic colorectal cancer. Eine Studie mit 2 Behandlungszweigen, um die Wirksamkeit von FOLFIRI (Chemotherapieschema mit den Wirkstoffen Folinsäure, Fluoruracil und Irinotecan) in Kombinationen mit jeweils einem bestimmten Antikörper (Cetuximab vs. Bevacizumab) in der Erstlinien-Behandlung des metastasierendem Darmkrebs.
Excerpt:
...- Histologically confirmed adenocarcinoma of colon and rectum - confirmation of a K-RAS wild type status ( in the primary tumor or in metastasis) -stage IV - general condition: 0-2 (ECOG/ WHO) - suitable for application of chemotherapy - written informed consent (first and second-line therapy) - Age 18- 75 - clinical or ambulant treatment - Life expectancy > 3 months - minimum one measurable indicator leasion according to RECIST. ...
Trial ID:
Source:
Title:
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
Excerpt:
...Topoisomerase-1 (topo-1) and K-ras, BRAF results obtained within 10 working days after registration`Number of patients in which the interval between registration and randomization (RZ) is ≤ 10 days`Efficacy of fluorouracil with vs without irinotecan hydrochloride, fluorouracil, and leucovorin calcium (IrMdG) in low topo-1 tumors`Progression-free survival of patients with high topo-1 tumors treated with IrMdG with or without oxaliplatin`Efficacy of IrMdG with vs without cetuximab in K-ras wildtype tumors`Efficacy of IrMdG with vs without bevacizumab in K-ras mutant tumors...
Trial ID:
More C2 evidence
Source:
Title:
Randomised study to investigate FOLFOXIRI plus Cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE 4.5) Randomisierte Studie zur Untersuchung von FOLFOXIRI plus Cetuximab oder FOLFOXIRI plus Bevacizumab als Erstlinientherapie des BRAF mutierten metastasierten kolorektalen Karzinoms(FIRE-4.5)
Excerpt:
...• Histologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum with metastases (metastatic colorectal cancer, mCRC), primarily non-resectable or surgery refused by the patient• RAS wild-type tumour status (KRAS and NRAS exons 2, 3, 4) (proven in the primary tumour or metastasis)• • BRAF V600E mutation-positive tumour (proven in the primary tumour or metastasis)• Age ≥18 years• ECOG performance status 0-1• Patients suitable for chemotherapy administration• Patient's written declaration of consent obtained • Estimated life expectancy > 3 months• Presence of at least one measurable reference lesion according to the RECIST 1.1 – criteria (chest X-ray in two planes or chest CT and abdominal CT 4 weeks or less before randomisation)• Primary tumour tissue available and patient consents to storage and molecular and genetic profiling of the tumour material. ...
Trial ID:
Source:
Title:
FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC
Excerpt:
...- RAS wild-type tumour status (KRAS and NRAS exons 2, 3, 4) (proven in the primary tumour or metastasis)...
Trial ID:
Source:
Title:
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Excerpt:
...- RAS wild-type tumor;...
Trial ID:
Source:
Title:
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
Excerpt:
...- pathologically confirmed colorectal carcinoma, with RAS wild type...
Trial ID:
Source:
Title:
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Excerpt:
......
Trial ID:
Source:
Title:
Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)
Excerpt:
...To be included in the study patients should present < 3 CTC in peripheral blood and RAS wild-type present in the sample of tumor tissue....
Trial ID:
Source:
Title:
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
Excerpt:
...To evaluate the correlation of values of angiogenesis-related growth factors in plasma with efficacy and adverse events`Progression-free survival among the RAS wild type subpopulation`Exploratory analysis of the relevance of tumor size and expression level of angiogenesis-related growth factors in plasma...
Trial ID:
Source:
Title:
Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study
Excerpt:
...- All Wild Type KRAS (exon 2 [codons 12-13], exon 3 [codons...
Trial ID:
Source:
Title:
A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab
Excerpt:
...- RAS wild-type...
Trial ID:
Source:
Title:
Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients
Excerpt:
...- K-ras wild-type...
Trial ID:
Source:
Title:
Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient
Excerpt:
...- KRAS wild-type status of primary colorectal cancer or related metastasis;...
Trial ID:
Source:
Title:
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
Excerpt:
...- Patients must have metastatic colorectal cancer that has been histologically or cytologically confirmed; confirmation may be from either the primary tumor or a metastasis; patients must have wild type KRAS...
Trial ID:
Source:
Title:
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Excerpt:
...- KRAS-Wildtype status...
Trial ID:
Less C2 evidence
Source:
Title:
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial
Published date:
02/26/2022
Excerpt:
...patients with irinotecan-refractory RAS-wildtype mCRC and no prior anti-EGFR therapy were randomized to cetuximab 500 mg/m2, bevacizumab 5 mg/kg, and irinotecan 180 mg/m2 (or previously tolerated dose) (CBI) versus cetuximab, irinotecan, and placebo (CI)...Median PFS was 9.7 versus 5.5 months for CBI and CI, respectively (1-sided log-rank P = .38; adjusted hazard ratio [HR] = 0.64; 95% confidence interval [CI], 0.25-1.66). Median OS was 19.7 versus 10.2 months for CBI and CI (1-sided log-rank P = .02; adjusted HR = 0.41; 95% CI, 0.15-1.09). ORR was 36.8% for CBI versus 11.8% for CI (P = .13). There was a statistically significant improvement in OS in favor of CBI compared with CI.
Secondary therapy:
irinotecan
DOI:
https://doi.org/10.1093/oncolo/oyab025
Trial ID:
